Takeda renews focus on neurology in Japan

There has been an update regarding an ongoing collaboration in neurology between Japanese pharma companies Takeda Pharmaceutical (TYO: 4502) and Shionogi (TYO: 4507).

Takeda has exercised an option to reacquire full rights to the oral attention-deficit/hyperactivity disorder products Intuniv (guanfacine) and Vyvanse (lisdexamfetamine).

The pharma major picked up the rights as part of its  giant acquisition of the British rare diseases company Shire, which completed in 2019.